Protagenic Therapeutics Inc PTIX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1996-12-18 |
| Shares Out. | 1,810,000 |
| Website | protagenic.com/ ↗ |
| Phone | 12129948200 |
| Employees | 5 |
| Revenue | $34,337 |
| Net Income | -$869,496 |
| Total Assets | $5.0M |
| Total Liabilities | $9.7M |
| Equity | -$4.7M |
About Protagenic Therapeutics Inc
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Protagenic Therapeutics Inc is a publicly traded company under the ticker symbol PTIX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2022-10-01)